Levamisole nanostructure lipid carrier gel for treating allergic rhinitis
By developing a nanostructured lipid carrier-modified sodium alginate hydrogel with levamisazole, the problems of instability and local irritation in the treatment of allergic rhinitis were solved, and the sustained release and efficient absorption of levamisazole were achieved, which improved the Treatment effects and avoid systemic side effects.
Patent Information
- Application Number
- CN202411130003.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
AI Technical Summary
Existing allergic rhinitis treatment drugs have problems such as instability in administration, local irritation and poor drug absorption, especially the oral and injection methods of levamisazole lead to systemic side effects, local administration is difficult to achieve effective concentration, and nanostructured lipid carriers Insufficient drug concentration and difficult release rate to control during local administration.
A nanostructured lipid carrier-modified sodium alginate hydrogel (LVM-NLC-gel) with levamisazole is developed to modify sodium alginate through benzene boric acid and dopamine to improve the adhesion, ductility and self-organism of the gel. Healing ability, forming a nanostructured lipid carrier gel with sustained release effect, achieving sustained release of levamisole and increasing the concentration of the drug at the target site.
The sustained release of levamisole is achieved, which extends the local action time of the drug, improves the treatment effect, avoids systemic side effects, enhances the concentration of the drug at the target site, and has no local irritation, and improves patient compliance.
Smart Images

Figure BDA0004997540810000061 
Figure BDA0004997540810000071 
Figure BDA0004997540810000072
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical biotechnology, and in particular relates to a levamisole nanostructured lipid carrier gel for treating allergic rhinitis. Background Art
[0002] Hypersensitive rhinitis, also known as allergic rhinitis (AR), is a non-infectious inflammatory disease of the nasal mucosa. It refers to a chronic inflammatory disease of the nasal mucosa that occurs when susceptible individuals come into contact with allergens, mainly induced by immunoglobulin E (IgE), with the participation of the body's immune active cells and cytokines, and with paroxysmal sneezing, runny nose and nasal congestion as the main symptoms. Drugs can be used to control symptoms, but there is no cure yet.
[0003] At present, the common AR treatment preparations in clinical practice mainly include the following: antihistamines such as loratadine, cetirizine, etc., which mainly relieve allergic symptoms by blocking histamine receptors, but common side effects include drowsiness, dry mouth, etc.; nasal corticosteroids such as budesonide, fluticasone, etc., have strong anti-inflammatory effects, but long-term use may lead to local immunosuppression, nosebleeds and other side effects; long-term use of antihistamines and nasal corticosteroids still has the problem of significantly reduced efficacy; immunotherapy such as sublingual immunotherapy can fundamentally improve the patient's allergic constitution, but the treatment cycle is long, the cost is high, and some patients have poor compliance with treatment.
[0004] Levamisole (LVM) is an immunomodulator with multiple pharmacological effects, such as enhancing immune function, anti-inflammatory and anti-allergic effects. In recent years, the application of LVM in the treatment of allergic diseases has received extensive attention. However, oral or injection administration of LVM may cause systemic side effects, such as nausea, headache, leukopenia, etc., while local administration is difficult to achieve effective concentrations, limiting its clinical application.
[0005] Dynamic changes of nasal mucosal bacteria in patients with chronic allergic rhinitis treated with inhaled levamisole [1] Report: Levamisole inhalation therapy can significantly change the nasal mucosal flora in patients with infectious-allergic rhinitis.
[0006] Levamisole ointment is effective for allergic rhinitis, affordable, and occupies a large market share. However, levamisole ointment is easily lost during use, resulting in unstable dosage; and long-term use of ointment containing penetration enhancers azone and propylene glycol may cause certain skin irritation, posing potential safety issues; however, due to its immunomodulatory effect, if it is developed into a nasal spray, direct nasal drops may cause local nasal mucosal irritation, dryness, and even occasional nose bleeding. In addition, the mucociliary clearance mechanism in the nasal cavity may remove the drug before it is absorbed, affecting the systemic absorption and therapeutic effect of the drug. Therefore, it is particularly necessary to develop new dosage forms for transdermal administration of levamisole to reduce irritation and improve therapeutic effects.
[0007] With the development of nanotechnology, the field of drug delivery has ushered in new breakthroughs. Nanostructured lipid carriers (NLC), as a new type of nano drug delivery system, have good biocompatibility and stability, can improve the solubility and bioavailability of drugs, and reduce the toxic side effects of drugs. However, when NLC is administered locally, there are still problems such as insufficient drug concentration and difficult to control release rate.
[0008] Sodium alginate (SA) is a natural polysaccharide separated from kelp, sargassum, etc. It has good biocompatibility. As a non-toxic, biodegradable natural polymer, it is a commonly used gel matrix. In addition, sodium alginate hydrogel has a loose and porous structure and can be used for drug loading and sustained drug release. However, sodium alginate hydrogel itself has problems such as poor self-healing, poor adhesion, and low mechanical strength. It is difficult to adhere closely to the skin surface, especially in special positions such as the nose and joints, and it cannot adapt to the deformation caused by muscle stretching during exercise and fall off. How to efficiently utilize the sustained release effect of sodium alginate hydrogel to obtain a hydrogel with high adhesion, ductility and self-healing ability, so as to better apply it to skin drug delivery to achieve the treatment of allergic rhinitis is a problem that needs to be solved at present.
[0009] In view of the defects of allergic rhinitis treatment drugs, it is very important and necessary to develop a new type of allergic rhinitis treatment drug.
[0010] References:
[0011] [1] He Zongde, Zheng Chunfang. Dynamic changes of nasal mucosal bacteria in patients with chronic infection-allergic rhinitis treated with levamisole inhalation [J]. International Journal of Otorhinolaryngology Head and Neck Surgery, 1983, (Issue 6). Summary of the invention
[0012] In view of the defects of existing drugs for treating allergic rhinitis, the present application studies and develops a levamisole nanostructured lipid carrier gel suitable for allergic rhinitis. To achieve the above purpose, the specific technical scheme of the present invention is as follows:
[0013] First aspect: preparation of LVM-NLC-modified sodium alginate hydrogel (LVM-NLC-gel)
[0014] (I) Construction of levamisole nanostructured lipid carrier (LVM-NLC)
[0015] (II) Synthesis of modified sodium alginate polymer
[0016] 1. Synthesis of phenylboronic acid modified sodium alginate, BA-SA
[0017] 2. Synthesis of phenylboronic acid-dopamine co-modified sodium alginate, BA-SA-DA
[0018] (III) Preparation of blank modified sodium alginate gel
[0019] (IV) Preparation of LVM-NLC-gel
[0020] Second, investigate the physical and chemical properties of LVM-NLC-gel
[0021] The texture analysis, rheological properties, appearance, ductility, recovery time, particle size, PDI, potential, pH value, viscosity, content determination, fault structure, and in vitro release of LVM-NLC-gel were investigated; high temperature, high humidity, and strong light irradiation experiments of LVM-NLC-gel were carried out.
[0022] Third, investigate the therapeutic effect and safety of LVM-NLC-gel on allergic rhinitis
[0023] (I) In vitro transdermal permeability of LVM-NLC-gel hydrogel
[0024] Nile red (NR) was used instead of LVM for in vitro permeability experiments.
[0025] 5h fluorescence: NR-NLC-gel>NR-NLC>NR-gel.
[0026] Analysis and conclusion: The in vitro permeability of the carrier was: NLC-gel>NLC>gel.
[0027] (II) Skin irritation test of LVM-NLC-gel
[0028] Results: Skin pathological examination under optical microscope showed no inflammatory cell infiltration, hemorrhage, or necrosis in the skin of the rats in the LVM-NLC group, LVM-gel group, and LVM-NLC-gel group.
[0029] Analysis and conclusion: LVM-NLC-gel has no skin irritation.
[0030] (III) Pharmacokinetic study of LVM-NLC-gel in beagle dogs
[0031] Results: The peak blood drug concentration and area under the chamber curve of the LVM-NLC-gel group were greater than those of the LVM-gel group and the LVM liniment group.
[0032] Analysis and conclusion: The absorption in vivo of LVM-NLC-gel was greater than that of LVM-gel and LVM liniment.
[0033] (IV) Pharmacodynamics of LVM-NLC-gel in the treatment of allergic rhinitis in rats
[0034] Analysis and conclusion: LVM-NLC-gel, oral cetirizine, and budesonide nasal drops are all effective in treating allergic rhinitis; LVM-NLC-gel is more effective than LVM-NLC and LVM-gel.
[0035] Compared with the prior art, the beneficial effects of this application are:
[0036] LVM-NLC-gel hydrogel developed in this application treats allergic rhinitis:
[0037] 1. LVM-NLC-gel can achieve sustained release of levamisole and prolong the local action time of levamisole. The pharmacokinetic results show that the area under the chamber curve LVM-NLC-gel>levamisole liniment and LVM-gel, Thereby improving the treatment effect;
[0038] 2. Transdermal administration improves patient compliance, avoids systemic side effects that may be caused by oral and injection administration, and increases drug concentration at the target site;
[0039] 3. LVM-NLC-gel hydrogel has no local irritation and adverse reactions.
[0040] In summary, LMSVM-NLC-gel hydrogel provides a new possible treatment for allergic rhinitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 , the particle size of LVM-NLC prepared under different process conditions;
[0042] Figure 2 , PDI of LVM-NLC prepared under different process conditions;
[0043] Figure 3 , the saturated solubility of LVM in different solid molten lipids and liquid lipids, among which,
[0044] A is the saturated solubility of LVM in different solid molten lipids,
[0045] B is the saturated solubility of LVM in different liquid lipids at room temperature;
[0046] Figure 4 , TEM image (left) and DLS particle size image (right) of LVM-NLC;
[0047] Figure 5 , pictures of LVM-NLC nanoparticles after freeze-drying and reconstitution with different freeze-drying protective agents, among which 1 is without freeze-drying protective agent, 2 is 1% lactose, 3 is 2% lactose, 4 is 3% lactose, 5 is 1% glucose, 6 is 2% glucose, 7 is 3% glucose, 8 is 1% mannitol, 9 is 2% mannitol, and 10 is 3% mannitol;
[0048] Figure 6 , FT-IR spectrum, where
[0049] A is the FT-IR spectrum of BA-SA,
[0050] B is the FT-IR spectrum of BA-SA-DA;
[0051] Figure 7 , BA-SA, DA-SA and BA-SA-DA H NMR spectra;
[0052] Figure 8 , BA-SA scanning spectrum and standard curve, where:
[0053] A is the scanning spectrum of BA-SA 200-600nm,
[0054] B is the BA-SA standard curve;
[0055] Fig. 9 , weight average molecular weight distribution diagram of SA;
[0056] Fig.10 , weight average molecular weight distribution diagram of BA-SA-DA;
[0057] Fig.11 , the apparent viscosity of different gels changes with shear rate (1-100 Hz);
[0058] Fig.12, the performance of BA-SA-DA hydrogel viscosity under different material properties;
[0059] Fig.13 , macroscopic performance evaluation of pH sensitivity, ductility, and self-healing properties of BA-SA-DA gel;
[0060] Fig.14 , characterization results of LVM-NLC-gel, among which,
[0061] A is the change of storage modulus and loss modulus of LVM-NLC-gel at pH = 5.0 and pH = 7.4 (0.001-10% strain, 1 Hz),
[0062] B is the change of G'>G" of LVM-NLC-gel in the sweep frequency range of 1~10 Hz (pH=7.4, 5% strain),
[0063] C is the change of storage modulus and loss modulus of LVM-NLC-gel in time-frequency cycle experiment (pH=7.4, 1Hz),
[0064] D is the macroscopic manifestation of pH sensitivity, ductility, and self-healing of LVM-NLC-gel;
[0065] Fig.15 , SEM images of LVM-NLC-gel (from left to right, 400, 500, 1000 times);
[0066] Fig.16 , the in vitro release of LVM-NLC-gel;
[0067] Fig.17 , fluorescence microscopy images of NR, NR-gel, NR-NLC, and NR-NLC-gel penetration in rat skin (×100, arrows indicate penetration direction);
[0068] Fig.18 , Skin irritation test results;
[0069] Fig.19 , pharmacokinetic experimental results;
[0070] Fig. 20 , blank group, model group, LVM-NLC-gel group, cetirizine group, budesonide group pharmacodynamic experimental results, among which,
[0071] A is the number of nose scratching in 30 minutes,
[0072] B is the number of sneezes in 30 minutes,
[0073] C is the IgE concentration in serum,
[0074] D is the concentration of IL-4 in serum;
[0075] Fig.21 , blank group, model group, LVM-NLC-gel group, LMS-NLC group, LVM-gel group pharmacodynamic experimental results, among which,
[0076] A is the weight growth rate,
[0077] B is the nasal symptom score,
[0078] C is the IgE concentration in serum,
[0079] D is the concentration of IL-4 in serum,
[0080] E: H&E staining of nasal mucosa and mast cell staining.
[0081] in Figure 1-Figure 21 middle,
[0082] *, **, *** and **** represent P<0.05, P<0.01, P<0.001 and P<0.0001, respectively, indicating that the difference between the two groups was statistically significant. DETAILED DESCRIPTION
[0083] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
[0084] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0085] All materials, reagents, etc. in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0086] Experimental Materials
[0087] 1. Reagents
[0088]
[0089]
[0090] 2. Instruments
[0091]
[0092]
[0093] Example 1: Construction of Levamisole Nanostructured Lipid Carrier (LVM-NLC)
[0094] 1. Preliminary process of preparing nanostructured lipid carriers by melt emulsification and ultrasonic method
[0095] The solid lipids and liquid lipids are mixed and heated to 5°C above the melting point of the solid lipids, and completely melted to form an oil phase; a surfactant is added to a certain amount of water and heated to the same temperature to form an aqueous phase; levamisole is added to the aqueous phase or the oil phase according to its properties; the aqueous phase is slowly added to the oil phase and mixed evenly to form colostrum. After the colostrum is sonicated with a probe ultrasonic device for a certain period of time, it is quickly placed in cold water to cool and form a nanostructured lipid carrier.
[0096] 2. Process Parameter Optimization
[0097] The effects of ultrasonic time, ultrasonic power, stirring time, stirring rate, cooling time and cooling temperature on the particle size and PDI of nanoparticles were investigated by single factor to determine the appropriate process parameters.
[0098] For solid lipids, different solid lipids (glyceryl monostearate, stearic acid, stearyl alcohol, ATO888, ATO5) were added to a vial, heated in a water bath to 5°C above their respective melting points until melted, and LVM was added to the vial in small amounts multiple times until saturated.
[0099] Results: Figure 1 and Figure 2 As shown in the figure, within a certain range, the particle size and PDI decrease with the increase of ultrasonic time, ultrasonic power and stirring time; the stirring rate has no significant effect on the particle size and PDI, and may only serve the purpose of mixing the water phase and the oil phase evenly; in addition, the ultrasonic preparation should be quickly cooled in ice water at 4°C, which is conducive to producing smaller particle size and PDI, rather than natural cooling at room temperature. The cooling time is about 15 minutes, and the extension of time will not significantly reduce the particle size and PDI. Therefore, the final process parameters are ultrasonic time of 3 minutes, ultrasonic power of 300W, stirring rate of 400rpm, cooling temperature of 4°C, and cooling time of 15 minutes.
[0100] 3. Lipid Selection
[0101] HPLC was used to determine the solubility of nano lipid carriers (LVM) in liquid lipids to select suitable lipids. TM 35-1, 90. Lauroglycol TM 90. M1944CS, Add excess LVM to the M2125CS, IPM) to reach supersaturation. Shake in a 37°C constant temperature shaker in the dark for 24 hours, then take out and centrifuge at 37°C, 10000 rpm for 15 minutes. Take the supernatant after centrifugation, filter with a 0.22 μm filter membrane, dilute with the mobile phase to an appropriate multiple and analyze by HPLC.
[0102] The solubility of LVM in glyceryl monostearate and M35-1 is 23.4 mg / g and 12.2 mg / g, respectively. Figure 3 It can be seen that the solubility of LVM in glyceryl monostearate and M35-1 is much greater than that in other lipids, so the solid lipid is determined as glyceryl monostearate and the liquid lipid is determined as M35-1. The greater the solubility of LMS in the carrier excipient, the higher the drug loading capacity can be, which will give it a greater drug concentration gradient difference inside and outside the skin, thereby promoting transdermal penetration.
[0103] 4. Selection of emulsifier
[0104] First, a single emulsifier is used to emulsify the mixed lipids. After screening out one or several emulsifiers with better emulsification effects, two emulsifiers with slightly different hydrophile-lipophile balance (HLB) values are selected for compound screening.
[0105] Results: The judgment indicators of surfactant emulsification of oil: no wall hanging on the wall of the glass, no milk residue; no floating oil or scum on the upper layer of the solution; no stratification of the original solution and the diluted solution after standing for a long time, which shows that the emulsification effect is good, as shown in Table 1, Tween 80 and Poloxamer 188 were finally selected.
[0106] Table 1: Emulsification state of mixed lipids by different emulsifiers
[0107]
[0108]
[0109] 5. Determination of LVM-NLC prescription
[0110] The Box-Behnken design method was used to investigate the effects of three factors (solid-liquid-lipid ratio, surfactant concentration, and milk fat ratio) on the CQA (critical quality attributes) of the final formulation. During the experimental design process, 17 different formulations of LVM-NLC were prepared and analyzed.
[0111] According to the optimized prescription, three batches of LVM-NLC were prepared, the particle size and PDI of LVM-NLC were measured, and the deviations between the predicted and actual values were calculated and compared.
[0112] Results: See Tables 2 and 3.
[0113] Table 2. Box-Behnken experimental design LMS-NLC prescription and experimental results
[0114] Serial number Solid-liquid lipid ratio Surfactant concentration (%) Milk fat ratio Particle size (nm) PDI 1 9 0.5 2.5 41.9 0.245 2 9 3.5 2.5 98.1 0.648 3 5 2 2.5 46.7 0.328 4 5 2 2.5 58 0.477 5 5 2 2.5 48.3 0.319 6 9 2 4 40.3 0.355 7 1 0.5 2.5 43.2 0.286 8 1 2 1 72.4 0.191 9 5 2 2.5 55.3 0.314 10 1 2 2 53.4 0.500 11 5 3.5 1 95.6 0.322 12 5 0.5 4 33.4 0.391 13 5 0.5 1 85.1 0.236 14 5 2 2.5 48.1 0.354 15 1 2 1 94.0 0.262 16 1 3.5 2.5 91.5 0.546 17 9 3.5 4 87.1 0.573
[0115] Table 3. Predicted and actual values of optimized prescriptions
[0116]
[0117] Conclusion: Nanostructured lipid carriers were successfully prepared by melt emulsification ultrasound method. The optimal prescription and preparation conditions were obtained through single factor investigation and Box-Behnken experimental design optimization: 78.4 mg of glyceryl monostearate and 10.4 mg of M35-1 were mixed and heated to 86°C to completely melt to form an oil phase. 87.5 mg of Tween 80 and 87.5 mg of poloxamer 188 were added to 25 mL of deionized water and heated to 86°C to form an aqueous phase. 50 mg of levamisole LVM was added to the aqueous phase, and the aqueous phase was slowly added to the oil phase and mixed evenly to form colostrum. The colostrum was ultrasonicated for 3 minutes with a probe ultrasonicator at an ultrasonic power of 300 W and a stirring rate of 400 rpm. It was quickly placed in 4°C cold water and cooled for 15 minutes to form a nanostructured lipid carrier, namely LVM-NLC.
[0118] Example 2, Characterization of LVM-NLC
[0119] 1. Particle size, PDI, Zeta potential and pH value
[0120] Take blank NLC and LMS-NLC respectively, dilute them to a suitable multiple with ultrapure water, and measure the particle size, PDI and Zeta potential with a laser particle size analyzer; take another appropriate amount of blank NLC and LMS-NLC, and measure their pH values with a pH meter at room temperature.
[0121] The results are shown in Table 4 and Figure 4 As shown by Figure 4 (Left) TEM image shows that the prepared LVM-NLC has a small particle size, is spherical, and is relatively uniform. The DLS laser particle size analyzer measures the average particle size of LVM-NLC to be 51.3nm, and the PDI is 0.244. Figure 4 (Right) is the DLS particle size diagram, which is consistent with the TEM image results.
[0122] Table 4. Particle size, PDI, Zeta potential and pH value of blank NLC and LVM-NLC
[0123] Characterization parameters NLC LVM-NLC Particle size (nm) 48.0±0.7 51.3±0.9 PDI 0.228±0.013 0.244±0.027 Zeta potential (mV) -4.8±0.3 -4.4±0.1 pH 5.22±0.12 4.33±0.25
[0124] 2. Content Determination
[0125] Accurately pipette 1 mL of LVM-NLC into a 10 mL EP tube, add 5 mL of acetonitrile and ultrasonically demulsify for 10 min, then transfer the solution completely into a 10 mL volumetric flask and dilute to the mark with acetonitrile. Detect the concentration using high performance liquid chromatography. Chromatographic conditions: chromatographic column: Amethyst C18-H column (5 μm, 4.6 mm × 150 mm); mobile phase: 0.05 mol / L potassium dihydrogen phosphate-acetonitrile (72:28); detection wavelength: 214 nm; flow rate: 1.0 mL / min; column temperature: 30 ° C; injection volume: 10 μL.
[0126] Results: The labeled percentage of LVM-NLC was determined to be (95.32±0.03)%, which was between 90% and 110% of the labeled amount and met the preparation standards.
[0127] 3. Viscosity
[0128] The viscosity of blank NLC and LVM-NLC was measured using the rotational mode of the rheometer. At room temperature (25°C), the sample was added into the gap of the cone-plate rotor (CP25), the shear rate was varied in the range of 1-100s-1, and the corresponding shear stress was recorded to obtain the viscosity value.
[0129] Results: The viscosities of blank NLC and LMS-NLC were 35.54±0.72mPa·s and 36.18±0.33mPa·s (average viscosity), respectively.
[0130] 4. Stability
[0131] The prepared LVM-NLC was diluted 10 times, 50 times, and 100 times, and its particle size and PDI were measured to investigate the effect of a large amount of water on its stability.
[0132] The prepared LVM-NLC was placed in a high-speed centrifuge at 10,000 rpm and 4° C. for 30 min, and the LVM-NLC was observed to see whether there was any stratification, precipitation or turbidity.
[0133] NLC may experience degradation of carrier materials, aggregation of particles, leakage and deterioration of drugs in water, etc., and freeze-drying it can significantly improve its stability. The prepared drug-loaded nanostructured lipid carrier LVM-NLC was pre-frozen at -20°C for a certain period of time, and then freeze-dried in a vacuum freeze dryer. After freeze-drying, it was re-dissolved with the same volume of distilled water, and its particle size and PDI were measured by a dynamic light scattering particle size analyzer.
[0134] Results: As shown in Table 5, the effect of dilution on the particle size and PDI of LVM-NLC was not obvious, indicating that even after dilution 100 times, LVM-NLC still retained its nanostructure, ensuring the stability of the subsequent LVM-NLC gel.
[0135] After centrifugation, the levamisole nanostructured lipid carrier had no stratification, drug precipitation and other phenomena, and had good centrifugal stability.
[0136] The pictures of LVM-NLC freeze-dried products with different freeze-dried protective agents and the reconstituted products are shown in the figure below. Figure 5 As shown, it can be seen that only the freeze-dried products with 2% and 3% mannitol are powder cakes with smooth and flat appearance, and they are clear and uniform liquids after reconstitution. The effects of different freeze-dried protective agents on the particle size and PDI of LVM-NLC nanoparticles are shown in Table 6. As the concentration of mannitol increases, the particle size and PDI of LVM-NLC will increase after reconstitution. Therefore, 2% mannitol was selected as the freeze-dried protective agent for the nanoparticle solution of LVM-NLC. The particle size and PDI of the freeze-dried powder after reconstitution are not much different from those before freeze-drying, indicating that the LVM-NLC freeze-dried powder has good redispersibility and the preparation can be stored in the state of freeze-dried portions.
[0137] Table 5. Particle size and PDI values of LVM-NLC diluted 10 times, 50 times and 100 times
[0138] Characterization parameters Dilute 10 times Dilute 50 times Dilute 100 times Particle size (nm) 49.7 50.6 60.2 PDI 0.244 0.246 0.310
[0139] Table 6. Effects of different lyophilization protectants on particle size and PDI of LMS-NLC nanoparticles
[0140] Lyoprotectant Particle size (nm) PDI Before freeze-drying 48.7 0.224 No lyoprotectant 113.9 0.301 1% Lactose 803.6 0.349 2% Lactose 1106.2 0.451 3% Lactose 1546.7 0.118 1% Glucose 359.2 0.259 2% Glucose 448.9 0.243 3% Glucose 796.3 0.354 1% Mannitol 52.6 0.248 2% Mannitol 54.9 0.246 3% Mannitol 79.6 0.287
[0141] Example 3: Synthesis and characterization of modified sodium alginate polymer
[0142] 1. Synthesis of phenylboronic acid modified sodium alginate (BA-SA)
[0143] 500 mg of sodium alginate (n-COOH = 2.3 mmol) was swollen in 50 mL of PBS buffer (pH 5.5) for 20 min. 360 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) and 50 mg of N-hydroxysuccinimide (NHS) were added for activation for 45 min. Then 160 mg of 3-aminophenylboronic acid (BA, MW = 136.94, n-NH2 = 1.1 mmol) was added and reacted at room temperature for 12 h. The obtained sol was dialyzed for purification and washed with purified water for 24 h using a dialysis bag with a molecular weight cutoff of 3,500 Da to remove free small molecules. The dialyzed sol was freeze-dried for 12 h to obtain a phenylboronic acid-modified sodium alginate freeze-dried product (BA-SA).
[0144] 2. Synthesis of phenylboronic acid-dopamine co-modified sodium alginate (BA-SA-DA)
[0145] 500 mg of sodium alginate (n-COOH=2.3 mmol) was swollen in 50 mL of PBS buffer (pH 5.5) for 20 min. 360 mg of EDC·HCl and 50 mg of NHS were added for activation for 45 min, followed by the addition of 160 mg of BA (MW=136.94, n-NH2=1.1 mmol), and the reaction was carried out at room temperature for 12 h. Subsequently, 244 mg of DA (MW, n-NH2), 240 mg of EDC·HCl and 144 mg of NHS were added, and the reaction was carried out at room temperature under N2 protection for 12 h. The obtained sol was dialyzed for purification, and the dialyzate was purified water. The dialyzed sol was freeze-dried for 12 h to obtain the freeze-dried product of sodium alginate co-modified with phenylboronic acid and dopamine (BA-SA-DA).
[0146] 3. Characterization of BA-SA and BA-SA-DA
[0147] Take appropriate amount of BA-SA, BA-SA-DA freeze-dried products and dried potassium bromide (1:100, wt%), put them in an agate mortar, grind and press them into tablets. Fourier transform infrared spectroscopy (FT-IR) was used to determine the molecular weight of BA-SA and BA-SA-DA polymers at 400-2000 cm -1 Infrared spectra in the wavenumber range.
[0148] Take an appropriate amount of the freeze-dried product of the gel matrix and dry potassium bromide (1:100, wt%), put them in an agate mortar, grind and press them into tablets. The Fourier transform infrared spectroscopy (FT-IR) was used to determine the molecular weight of BA-SA and BA-SA-DA polymers at 400-2000 cm -1 Infrared spectra in the wavenumber range.
[0149] Take an appropriate amount of freeze-dried products of BA-SA and BA-SA-DA, dissolve them in heavy water (D2O), transfer them to a nuclear magnetic resonance tube, and collect nuclear magnetic resonance hydrogen spectrum (1H-NMR) data.
[0150] Results: By Figure 6 A shows that 1718cm -1 The absorption peak at 1604cm -1 The peak is the C=C stretching vibration of the aromatic ring skeleton, 1461 cm -1 and 1035cm -1 The peaks were attributed to the stretching vibrations of the amide bond and the boron-oxygen bond, respectively, which preliminarily confirmed the synthesis of the BA-SA product;
[0151] Depend on Figure 6 B shows that 1712cm -1 The absorption peak at 1610 cm -1The peak is the C=C stretching vibration of the aromatic ring skeleton; 1459cm -1 、1236cm -1 and 1031cm -1 The peaks were attributed to the stretching vibrations of the amide bond, the CO bond of phenol, and the boron-oxygen bond. It was preliminarily determined that the BA-SA-DA product was successfully synthesized.
[0152] In 1H-NMR ( Figure 7 ), the 7.3-7.7ppm multiple peak is the characteristic peak of the proton of the BA benzene ring, and the 3.5-4.0ppm is the characteristic peak of the proton of the sodium alginate skeleton, which can prove that BA is connected to SA; the 6.4-6.7ppm multiple peak is the characteristic peak of the proton of the DA benzene ring, and there is also a characteristic peak of sodium alginate at 3.5-4.0ppm, which can prove that DA is connected to SA; the simultaneous presence of the characteristic peaks of the above products can prove that BA and DA are both connected to SA.
[0153] The grafting rate of BA and DA on sodium alginate was determined by UV-visible spectrophotometer. Taking BA-SA as an example, BA and BA-SA were prepared into aqueous solutions, and the full wavelength of 200-800nm was scanned to determine the maximum absorption wavelength of BA and BA-SA. 0.010-0.1mg / mL BA solution was prepared to prepare a standard curve, and the grafting rate of BA in BA-SA was determined and calculated.
[0154] Results: By Figure 8 A shows that SA has no obvious absorption in the UV-visible absorption wavelength range, but BA has obvious UV absorption at 294nm, which is consistent with the theory. According to the standard curve ( Figure 8 B) The grafting rate of the synthesized BA-SA was calculated to be about 3.1%.
[0155] Depend on Fig. 9 and 10 It can be seen that the weight average molecular weight (MW) of SA is 469523, the weight average molecular weight (MW) of BA-SA-DA is 636454, and the grafting rate of BA-SA-DA polymer is calculated to be about 25.59%.
[0156] Example 4. Preparation and characterization of modified sodium alginate blank hydrogel
[0157] 1. Preparation of blank modified sodium alginate gel
[0158] 500 mg of BA-SA and 500 mg of BA-SA-DA freeze-dried products were swollen with 50 mL of PBS buffer (pH = 5.5) for 12 h, and 10 mL of 0.1 M NaOH solution was added dropwise after swelling, and the mixture was thoroughly stirred to obtain BA-SA and BA-SA-DA hydrogels.
[0159] 2. Characterization of blank modified sodium alginate gel
[0160] (I) Texture analysis
[0161] Texture analysis using cylindrical probe (sharp edge, diameter: 12.7mm)
[0162] The test parameters are: speed before the test is 1 mm / s, test speed is 0.5 mm / s, speed after the test is 0.5 mm / s, interval time is 5.00 s, and compression distance is 2.00 mm.
[0163] Before measurement, the sample was placed in a beaker (height: 2 cm), and two compression cycle tests were performed on the sample. The applied pressure (load: 5 g) was recorded, and the measurement was repeated 3 times for each sample.
[0164] Results: As shown in Table 7, the hardness of BA-SA-DA gel had no significant difference with BA-SA gel, commercially available compound dexamethasone acetate gel and commercially available indomethacin bubonic paste, but the adhesion and elasticity of BA-SA-DA gel were better than those of other gels, so it was preliminarily judged that BA-SA-DA gel had the best performance.
[0165] Table 7. Textural properties of commercially available gel / gel patches and modified sodium alginate gel matrices
[0166]
[0167]
[0168] (ii) Apparent viscosity
[0169] The apparent viscosity of modified sodium alginate gel and commercially available gel / gel patch was investigated using the oscillation mode of the rheometer. At room temperature (25°C), the sample was added into the gap of the flat rotor (PP25), and the shear rate was gradually increased from 0 Hz to 100 Hz. The apparent viscosity was recorded and the measurement was repeated 3 times for each sample.
[0170] result: Fig.11 The viscosity of the sample gel decreases with the increase of shear rate, indicating that they are all pseudoplastic fluids (shear-thinning fluids) among non-Newtonian fluids, which can well meet the application of gel in daily life. Before use, the viscosity is small and easy to operate. After application, the viscosity increases and it is not easy to fall off. Fig.12 The results showed that BA-SA-DA hydrogel had excellent adhesion between skin and plastic, metal and metal, plastic and plastic, and glass and glass, indicating that BA-SA chemically modified with DA has greatly improved adhesion while maintaining other excellent properties. Therefore, BA-SA-DA was selected as the gel matrix for subsequent research.
[0171] (III) Appearance and extension ability of gel
[0172] Change the pH value of the gel solution and observe the appearance of the gel at pH = 5.5 and pH = 7.4. At pH = 7.4, place the prepared gel on the joint, move the joint, and observe its extension ability; and cut it in half to observe the time it takes to return to its original state.
[0173] Results: Fig.13 As shown in A1, when pH = 5.5, the prepared BA-SA-DA gel is in a sol state. Fig.13 As shown in A2, when the pH is 7.4, it is in a gel state, indicating that it has pH responsiveness. Fig.13 As shown in B, the gel was applied to the joint surface and was found to fit closely to the skin without affecting joint movement, indicating good ductility. Fig.13 As shown in C, the gel was cut into three sections and was able to return to its original shape in a short period of time, indicating that it has excellent healing ability.
[0174] Example 5. Preparation of LVM-NLC-loaded modified sodium alginate hydrogel (LVM-NLC-gel) The preparation method of LVM-NLC-gel is as follows: at pH = 5.5, take 200 mg of LVM-NLC and 10 g of blank modified sodium alginate gel (sol state), stir and mix them thoroughly, and adjust the pH value of the solution to neutral with 0.1 M NaOH solution to obtain LVM-NLC-gel.
[0175] Example 6. Characterization of LVM-NLC-gel
[0176] 1. Texture Analysis
[0177] Texture analysis uses a cylindrical probe (sharp edge, diameter: 12.7mm). Test parameters are: pre-test speed 1mm / s, test speed 0.5mm / s, post-test speed 0.5mm / s, interval time 5.00s, compression distance 2.00mm. Before measurement, the sample is placed in a beaker (height: 2cm), and two compression cycle tests are performed on the sample, and the applied pressure (load: 5g) is recorded. Each sample is measured 3 times.
[0178] 2. Rheological properties
[0179] The rheological properties of LVM-NLC-gel were investigated in oscillation mode. The method for determining the apparent viscosity is shown in Example 4. At room temperature (25°C), the sample was added into the gap of the flat rotor (PP25).
[0180] First, the pH response ability of LVM-NLC-gel was investigated: the storage modulus (G') and loss modulus (G") of LVM-NLC-gel were measured with pH at pH = 5.5 and pH = 7.4 in the strain range of 0.01% to 10%. The results are shown in Fig.14 A;
[0181] Then the viscoelasticity of LVM-NLC-gel was investigated: at pH = 7.4, the strain was fixed at 5%, and the changes of G' and G" were investigated in the scanning frequency range of 0.1 to 10 Hz. The results are shown in Fig.14 B;
[0182] Finally, the self-healing property of LVM-NLC-gel was investigated by time-frequency cycling experiment: the frequency was fixed at 1 Hz, and the gel structure was stabilized by low shear strain (5%) within 0 to 5 min. The gel structure was destroyed by increasing shear strain (500%) within 5 to 7 min. The low shear strain was restored within 7 to 17 min. This cycle was repeated three times to observe the changes in G' and G". The results are shown in Fig. Fig.14 C.
[0183] 3. Appearance, extension ability, and recovery time
[0184] 1. Methods
[0185] The pH value of the LVM-NLC-gel solution was changed, and the appearance of the LVM-NLC-gel was observed at pH = 5.5 and pH = 7.4. At pH = 7.4, the prepared LVM-NLC-gel was placed on the joint, and the joint was moved to observe its extension ability; and it was cut in half to observe the time required for it to return to its original state.
[0186] (II) Results
[0187] Results Fig.14 D.
[0188] 4. Particle size, PDI, potential, pH value, viscosity and content determination of LVM-NLC-gel
[0189] The particle size, PDI, potential, pH value, viscosity and content of LVM-NLC-gel were determined by the same experimental methods as those in Example 2 and the characterization of LVM-NLC. The results are shown in Table 8.
[0190] Table 8. Particle size, PDI, Zeta potential, pH value, viscosity and content of LVM-NLC-gel
[0191] Characterization parameters LVM-NLC-gel Particle size (nm) 53.28±0.9 PDI 0.258±0.039 Zeta potential (mV) -4.3±0.3 pH 7.56±0.14 Viscosity 221.12±3.07Pa·s content (100.25±0.04)%
[0192] 5. Fault structure
[0193] The freeze-dried LVM-NLC-gel was cut flat and adhered to the conductive glue and sprayed with gold. The cross-sectional structure of the gel was observed using a scanning electron microscope. The results are as follows: Fig.15 shown.
[0194] 6. In vitro release
[0195] 1. Methods
[0196] Using dynamic membrane dialysis, LVM-NLC, LVM-gel and LVM-NLC-gel (all containing 5 mg LVM) were placed in a dialysis bag, the air bubbles were exhausted, the two ends were tied tightly, and the bags were placed in a 100-mL centrifuge tube. 40 mL of PBS buffer (pH = 6.8) was used as the release medium (1 mL of the release medium was added to the dialysis bag for the gel preparation group). The bags were placed in a 37°C water bath constant temperature oscillator with a rotation speed of 150 rpm. Samples were taken at the set time points of 10, 20, 40, 60, 90, 120, and 240 min, and 2 mL of the release medium was taken out each time. At the same time, an equal amount of fresh medium at the same temperature was supplemented. The taken out medium was filtered through a 0.45 μm filter membrane, and the filtrate was taken for high performance liquid chromatography injection to determine the LVM hydrochloride content in the medium, and the cumulative release of LVM hydrochloride was calculated.
[0197] (II) Results
[0198] The results are as follows Fig.16 As shown,
[0199] The release of LVM-NLC gradually increased from 0 to 40 minutes, reaching the maximum release at 40 minutes, and the maximum release was about 100%;
[0200] The release of LVM-gel and LVM-NLC-gel increased rapidly from 0 to 40 minutes, and slowly from 60 to 240 minutes, with the maximum release being about 75%.
[0201] (III) Analysis and Results
[0202] LVM-NLC-gel has a sustained-release effect, which prolongs the duration of action in the local affected area.
[0203] VII. Experiments on high temperature, high humidity and strong light exposure of LMS-NLC-gel
[0204] 1. Methods
[0205] The high temperature, high humidity and strong light irradiation experiments of LVM-NLC-gel were carried out in accordance with the General Chapter 9001 of the 2020 edition of the Chinese Pharmacopoeia, Part IV, “Guidelines for Stability Testing of Drug Substances and Preparations”.
[0206] (II) Results
[0207] The high temperature experiment of LVM-NLC-gel is shown in Table 5.
[0208] Table 9. LVM-NLC-gel high temperature test results
[0209]
[0210] The LVM-NLC-gel high humidity experiment is shown in Table 10.
[0211] Table 10. High humidity test results of LVM-NLC-gel
[0212]
[0213] The strong light irradiation experiment of LVM-NLC-gel is shown in Table 11.
[0214] Table 11. Results of the strong light irradiation experiment of LVM-NLC-gel
[0215]
[0216]
[0217] Example 7: In vitro percutaneous permeability of LVM-NLC-gel hydrogel
[0218] 1. Methods
[0219] Take healthy male rats (about 200g), carefully shave the long hair on the abdominal skin with a pet shaver, and then use a depilatory cream to remove the remaining hair. After two days of rest, dislocate and kill, and take the abdominal skin. Carefully remove the subcutaneous tissue and lay the skin flat on the filter paper. Cut the skin into appropriate sizes according to the size of the diffusion cell, check the integrity of the skin, and finally put it in a sealed bag and put it in a refrigerator (-20℃) for freezing.
[0220] Fluorescence microscopy was used to observe the penetration of the preparations in rat skin. Different preparations (blank, gel, NLC and NLC-gel) and 1 mL of free Nile red solution (containing the same concentration of Nile red, 10 μmol / L, referred to as NR) were placed in the supply pool. The skin tissue was removed at 30 min, 2 h, and 5 h, and the residual preparation on the skin surface was wiped off with filter paper, and washed with ethanol and ultrapure water. The treated skin samples were embedded with OCT embedding agent (the skin was embedded upright), placed in a -20°C refrigerator and frozen overnight, and sliced with a frozen microtome (20 μm). Observed under a fluorescence microscope, magnified 100 times under the same background exposure rate, and collected images.
[0221] 2. Results
[0222] like Fig.17As shown, fluorescence at 2h and 5h
[0223] NR-NLC-gel group>NR-NLC group>NR-gel group.
[0224] 3. Analysis and Conclusion
[0225] In vitro permeability: NLC-gel>NLC>gel.
[0226] Example 8: Study on skin irritation of LVM-NLC-gel hydrogel
[0227] 1. Methods
[0228] SD rats were selected for a 7-day skin irritation experiment. Before administration, the hair on the back of the rats was carefully shaved, and the hair removal area was approximately 2×2 cm. 2 . Nine SD rats were randomly divided into three groups, three rats in each group, namely the negative control group (0.9% saline), LVM-NLC group, LVM-gel group and LVM-NLC-gel group (dosage: 60 mg / kg). After 6 hours of daily administration of the corresponding drugs, the skin administration site was observed for abnormalities such as erythema and edema. Seven days after administration, the SD rats were killed by dislocation, and the skin of the administration site was removed for routine paraffin sections and H&E staining. Skin pathology was performed under an optical microscope to observe whether the skin had inflammatory cell infiltration, bleeding, necrosis, etc.
[0229] 2. Results
[0230] like Fig.18 As shown, there was no inflammatory cell infiltration, hemorrhage, or necrosis in the skin of the negative control group, LVM-NLC group, LVM-gel group, and LVM-NLC-gel group.
[0231] 3. Analysis and Conclusion
[0232] LVM-NLC, LVM-gel and LVM-NLC-gel are non-irritating to skin.
[0233] IV. Comparison of LVM-NLC-gel and levamisole intragastric administration
[0234] Results: LVM-NLC-gel is safer than levamisole for the treatment of allergic rhinitis via oral administration.
[0235] Example 9: Pharmacokinetic study of LVM-NLC-gel hydrogel in beagle dogs
[0236] 1. Methods
[0237] Four healthy beagles were given LVM Liniment in the first week, LVM-gel in the second week, and LVM-NLC-gel in the third week, with a dosage of 18.8 mg / kg. Two days before administration, the hair on the upper left abdomen of the dogs was removed with a shaver, and the dogs were kept for later use. The liniment group was evenly applied to the shaved area; the gel patch was tightly attached to the shaved area of the abdomen, and the dogs were put on a cotton vest to prevent the patch from being torn off. No food or water was allowed for 12 hours before administration. 1 mL of blood was collected from the lower vein of the inner forelimb of the dog before administration and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, and 36 hours after administration, respectively, in a sodium heparinized tube, centrifuged at 3500rpm for 10 minutes, and the upper plasma was removed for determination.
[0238] 2. Results
[0239] like Fig.19 As shown, the peak time of blood drug concentration in LVM-NLC-gel group was 4-6h; the peak time of blood drug concentration in levamisole ointment group was 0.5h; and the peak time of blood drug concentration in LVM-gel group was 1h.
[0240] The area under the chamber curve and the peak blood drug concentration were as follows: LVM-NLC-gel group > levamisole ointment group > LVM-gel group.
[0241] 3. Analysis and Conclusion
[0242] Compared with levamisole ointment and LVM-gel, LVM-NLC-gel has higher blood drug concentration, maintains high blood drug concentration for longer time, and has a larger area under the chamber curve, so it is more beneficial for the treatment of allergic rhinitis.
[0243] Example 10: Pharmacodynamics of LVM-NLC-gel in the treatment of allergic rhinitis in rats
[0244] 1. Methods
[0245] 1. 30 healthy clean-grade SD rats were randomly divided into 5 groups: blank group, model group, LVM-NLC-gel group, cetirizine group, and budesonide group, with 6 rats in each group. The rats were treated with 60 mg / ml LVM-NLC-gel, 1.04 mg / kg cetirizine by oral gavage, and 0.027 mg / kg budesonide by nasal drops, 3 hours after nasal drops stimulation, once a day.
[0246] 2. 30 healthy clean-grade SD rats were randomly divided into 5 groups: model group, treatment group (LVM-NLC group and LVM-NLC-gel group), reference group (ointment group), and blank group, with 6 rats in each group. LVM-gel patch and LVM-NLC-gel patch (60 mg / mL) were given for treatment, 3 hours after nasal drop stimulation, once a day.
[0247] 2. Results
[0248] like Fig. 20 As shown, the pharmacodynamic experimental results of the blank group, model group, LVM-NLC-gel group, cetirizine group, and budesonide group were compared.
[0249] like Fig. 20 As shown in A, the number of nose scratching in 30 minutes:
[0250] The difference between the model group and the blank group was significant, P < 0.0001.
[0251] There was a significant difference between the LVM-NLC-gel group and the model group, P < 0.01.
[0252] There was a significant difference between the cetirizine group and the model group, P < 0.001.
[0253] The difference between the budesonide group and the model group was significant, P < 0.001;
[0254] like Fig. 20 As shown in B, the number of sneezes in 30 minutes:
[0255] The difference between the model group and the blank group was significant, P < 0.001.
[0256] There was a significant difference between the LVM-NLC-gel group and the model group, P < 0.05.
[0257] There was a significant difference between the cetirizine group and the model group (P<0.01).
[0258] The difference between the budesonide group and the model group was significant, P < 0.01;
[0259] like Fig. 20 As shown in C, IgE concentration:
[0260] The difference between the model group and the blank group was significant, P < 0.0001.
[0261] There was a significant difference between the LVM-NLC-gel group and the model group, P < 0.01.
[0262] There was a significant difference between the cetirizine group and the model group, P < 0.001.
[0263] The difference between the budesonide group and the model group was significant, P < 0.001;
[0264] like Fig. 20 As shown in D, the concentration of IL-4 in serum:
[0265] The difference between the model group and the blank group was significant, P < 0.0001.
[0266] The difference between the LVM-NLC-gel group and the model group was significant (P<0.001).
[0267] There was a significant difference between the cetirizine group and the model group, P < 0.001.
[0268] The difference between the budesonide group and the model group was significant, P < 0.0001;
[0269] like Fig.21 As shown, the pharmacodynamic experimental results of the blank group, model group, LVM-NLC-gel group, LMS-liniment group, and LVM-gel group were compared.
[0270] like Fig.21 As shown in A, the weight growth rate is:
[0271] There was a significant difference between the model group and the blank group, P < 0.01
[0272] like Fig.21 B shows the nasal symptom score:
[0273] After LVM-NLC-gel administration, the nasal score was lower than that before administration.
[0274] like Fig.21 As shown in C, the IgE concentration in serum
[0275] Compared with the model group, serum IgE was lower after LVM-NLC-gel administration.
[0276] like Fig.21 D shows the serum IL-4 concentration.
[0277] Compared with the model group, the serum IL-4 level was lower after LVM-NLC-gel administration.
[0278] like Fig.21 E: H&E staining of nasal mucosa and mast cell staining
[0279] Blank group: The rat nasal mucosa was intact, smooth, without inflammatory cell infiltration, and the olfactory epithelium was visible. Model group: Under an optical microscope, it can be seen that the rat nasal mucosal epithelial structure was defective, the epithelial cells were atrophied, necrotic or shed, the subepithelial connective tissue was coagulated and necrotic, the glands were hyperplastic and swollen, the inflammatory cells and glandular tissue were compressed and deformed, the blood vessels were dilated and occluded, or there was interstitial bleeding and a large number of inflammatory cells infiltrated. Treatment group: The rat nasal mucosal tissue was mostly normal nasal mucosa, with olfactory epithelium and its attached microvessels and a small number of glands, or a small amount of inflammatory cell infiltration.
[0280] Toluidine blue staining of the nasal mucosa showed that there was almost no mast cell infiltration in the normal control group, while a large number of mast cell infiltrations were observed in the model group, and even some cytoplasmic granules were released outside the cell membrane. The number of mast cells in the treatment group was significantly reduced.
[0281] 3. Analysis and Conclusion
[0282] 1. LVM-NLC-gel, cetirizine and budesonide are all effective in treating allergic rhinitis.
[0283] 2. LVM-NLC-gel is more effective than LMS-NLC and LVM-gel in treating allergic rhinitis.
Claims
1. A method for preparing LVM-NLC-gel, comprising: (1) Building LVM-NLC 78.4 mg of glyceryl monostearate and 10.4 mg of M35-1 were mixed and heated to 86°C to completely melt to form an oil phase, 87.5 mg of Tween 80 and 87.5 mg of poloxamer 188 were added to 25 mL of deionized water and heated to 86°C to form an aqueous phase, 50 mg of levamisole LVM was added to the aqueous phase, the aqueous phase was slowly added to the oil phase, and mixed evenly to form colostrum, the colostrum was ultrasonicated for 3 minutes with a probe ultrasonicator, the ultrasonic power was 300 W, the stirring rate was 400 rpm, and it was quickly put into 4°C cold water and cooled for 15 minutes to form a nanostructured lipid carrier, i.e., LVM-NLC; (2) Synthesis of modified sodium alginate polymer A. Synthesis of phenylboronic acid modified sodium alginate, BA-SA 500 mg of sodium alginate with n-COOH=2.3 mmol was swollen in 50 mL of PBS buffer at pH 5.5 for 20 min, 360 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDC·HCl and 50 mg of N-hydroxysuccinimide NHS were added for activation for 45 min, and then 160 mg of 3-aminophenylboronic acid BA with MW=136.94 and n-NH2=1.1 mmol was added, and the mixture was reacted at room temperature for 12 h. The obtained sol was dialyzed for purification, and washed with purified water for 24 h using a dialysis bag with a molecular weight cutoff of 3,500 Da to remove free small molecules. The dialyzed sol was freeze-dried for 12 h to obtain a phenylboronic acid-modified sodium alginate freeze-dried product, namely, BA-SA freeze-dried product; B. Synthesis of phenylboronic acid-dopamine co-modified sodium alginate, BA-SA-DA 500 mg of sodium alginate with n-COOH=2.3 mmol was swollen in 50 mL of PBS buffer at pH 5.5 for 20 min, 360 mg of EDC·HCl and 50 mg of NHS were added for activation for 45 min, then 160 mg of BA with MW=136.94 and n-NH2=1.1 mmol was added, and the mixture was reacted at room temperature for 12 h, then 244 mg of dopamine hydrochloride DA with MW=189.64 and n-NH2, 240 mg of EDC·HCl and 144 mg of NHS were added, and the mixture was reacted at room temperature under N2 protection for 12 h, the obtained sol was dialyzed for purification, and a dialysis bag with a molecular weight cutoff of 3,500 Da was used to wash with purified water for 24 h to remove free small molecules, and the dialyzed sol was freeze-dried for 12 h to obtain a lyophilized product of sodium alginate co-modified with phenylboronic acid and dopamine, namely, a lyophilized product of BA-SA-DA; (3) Preparation of blank modified sodium alginate gel 500 mg of BA-SA and 500 mg of BA-SA-DA freeze-dried products were swollen with 50 mL of PBS buffer at pH = 5.5 for 12 h, and 10 mL of 0.1 M NaOH solution was added dropwise after swelling, and stirred well to obtain blank modified sodium alginate gel; (4) Preparation of LVM-NLC-gel When pH=5.5, 200 mg of LVM-NLC and 10 g of blank modified sodium alginate gel in a sol state were taken and stirred thoroughly, and the pH value of the solution was adjusted to neutral with 0.1 M NaOH solution to obtain LVM-NLC-gel.
2. Use of the LVM-NLC-gel as claimed in claim 1 in preparing a drug for treating allergic rhinitis.
3. The preparation method according to claim 1, characterized in that: The particle size and PDI of the LVM-NLC-gel are respectively an average particle size of 53.28±0.9 nm and a PDI of 0.258±0.
039.
4. The preparation method according to claim 1, characterized in that: The content of the LVM-NLC-gel is 100.25%.
5. The preparation method according to claim 1, characterized in that: The results of the hydrogel skin irritation study showed that there was no inflammatory cell infiltration, bleeding, or necrosis in the skin after administration of the LVM-NLC-gel.
6. The preparation method according to claim 1, characterized in that: The results of the in vivo pharmacokinetic study in beagle dogs showed that the LVM-NLC-gel had a higher blood drug concentration, maintained a higher blood drug concentration for a longer time, and had a larger area under the chamber curve than the levamisole ointment and LVM-gel.
